Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 1:22:451-465.
doi: 10.17179/excli2023-6098. eCollection 2023.

Genomic evolution of the SARS-CoV-2 Variants of Concern: COVID-19 pandemic waves in India

Affiliations
Review

Genomic evolution of the SARS-CoV-2 Variants of Concern: COVID-19 pandemic waves in India

Pooja Bhardwaj et al. EXCLI J. .

Abstract

SARS-CoV-2 has mutated rapidly since its first case report in Wuhan, China, leading to the emergence of an indefinite number of variants. India has witnessed three waves of the COVID-19 pandemic. The country saw its first wave of SARS-CoV-2 illness from late January 2020 to February 2021. With a peak surge of cases in mid-September 2020, India recorded more than 11 million cases and a death toll of more than 0.165 million at this time. India faced a brutal second wave driven by the emergence of highly infectious SARS-CoV-2 variants B.1.617.2 (Delta variant) and the third wave with the leading cause of BA.2 (Omicron variant), which has led to an unprecedented rise in COVID-19 cases in the country. On September 14, 2022, India recorded a cumulative 44.51 million cases of COVID-19 with more than 0.528 million deaths. The discovery of common circulating mutants is facilitated by genome sequencing. The changes in the Spike surface glycoprotein recombinant binding domains served as the critical alterations, resulting in enhanced infectivity and transmissibility, with severe clinical effects. Further, the predominant mutation in the SARS-CoV-2 spike protein; the D614G strains served as a model for vaccine development. The mutation of the Wuhan strain to the Variant of Concern led to a significant increase in SARS-CoV-2 infections. In addition, there was a shift in the age group affected by SARS-CoV-2 variant infection. The current review summarized the COVID-19 pandemic's Variant of Concern and the advent of SARS-CoV-2 in India.

Keywords: COVID-19; India; SARS-CoV-2; Spike protein; Variant of Concern.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Table 1
Table 1. List of SARS-CoV-2 variants currently designated as Variants of Concern, Variants of Interest, and Variants under Monitoring
Figure 1
Figure 1. Trend of emerged SARS-CoV-2 GISAID clades (Circle) and their respective marker mutations (Box). Bold letters in the box represent the gene in which mutation is depicted.
Figure 2
Figure 2. Different nomenclature systems used for classification of SARS-CoV-2 variants and their evolutionary relationship. The GISAID classification refers to key mutations observed during evolution, Nextstrain classification refers to the year and clades evolved and Phylogenetic assignment of named global outbreak lineage (PANGOLIN) classification followed Rambaut et al. (2020).
Figure 3
Figure 3. Timelines for the Variant of Concerns evolved during the COVID-19 pandemic with their respective country reported first. Bar graphs represent key mutations in spike glycoprotein with respect to wild type. Bar graph of wild type showed S1 fragment containing SS- signal sequence, NTD- N-terminal domain, RBD- Receptor-binding domain, S1/S2 cleavage site and S2 fragment with Two HR-Heptad repeats (HR1 & HR2), TM-Transmembrane anchor, CT- C-terminal

References

    1. Andrews M, Areekal B, Rajesh K, Krishnan J, Suryakala R, Krishnan B, et al. First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res. 2020;151:490–492. - PMC - PubMed
    1. Bano I, Sharif M, Alam S. Genetic drift in the genome of SARS COV-2 and its global health concern. J Med Virol. 2022;94:88–98. - PMC - PubMed
    1. Behera P, Singh AK, Subba SH, Mc A, Sahu DP, Chandanshive PD, et al. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Hum Vaccin Immunother. 2022;18(1):2034456. - PMC - PubMed
    1. Bhattacharya M, Chatterjee S, Sharma AR, Lee SS, Chakraborty C. Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of infection, transmission, immune escape, and mutational landscape. Folia Microbiol (Praha) 2023;68(1):17–28. - PMC - PubMed
    1. Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2023;614(7948):521–529. - PMC - PubMed

LinkOut - more resources